Rabbit Recombinant Monoclonal JAK1 phospho Y1034 + Y1035 antibody. Suitable for Flow Cyt and reacts with Mouse, Human samples. Immunogen corresponding to Synthetic Peptide within Human JAK1 phospho Y1034 + Y1035.
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49.88% PBS, 0.1% BSA
Flow Cyt | |
---|---|
Human | Tested |
Mouse | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 0.001-1 µg/mL | Notes - |
Species Human | Dilution info 0.001-1 µg/mL | Notes - |
Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529) as well as interleukin (IL)-10 receptor (PubMed:12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed:7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:16239216, PubMed:32750333, PubMed:8232552).
JAK1A, JAK1B, JAK1, Tyrosine-protein kinase JAK1, Janus kinase 1, JAK-1
Rabbit Recombinant Monoclonal JAK1 phospho Y1034 + Y1035 antibody. Suitable for Flow Cyt and reacts with Mouse, Human samples. Immunogen corresponding to Synthetic Peptide within Human JAK1 phospho Y1034 + Y1035.
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 49.88% PBS, 0.1% BSA
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
JAK1 also known as Janus Kinase 1 plays an essential role in transmitting signals within cells. It is a tyrosine kinase enzyme with a molecular weight of approximately 130 kDa. JAK1 is expressed broadly in various tissues and is involved in cytokine receptor signaling. The kinase activity of JAK1 gets activated upon cytokine binding to its respective receptor which leads to phosphorylation events and downstream signaling cascades.
This enzyme participates significantly in the immune response and hematopoiesis by being part of the JAK-STAT signaling pathway complex. When activated JAK1 phosphorylates specific tyrosine residues on the receptor creating docking sites for STAT proteins which then get phosphorylated by JAK1. This phosphorylation allows STAT proteins to dimerize and translocate to the nucleus affecting gene expression involved in growth survival and differentiation processes.
JAK1 is importantly engaged in the JAK-STAT pathway and the Interferon signaling pathway. Within these pathways JAK1 collaborates closely with other proteins like JAK2 TYK2 and STAT proteins. It acts as a mediator of the cellular response to a variety of cytokines and growth factors playing a role in the regulation of immune responses and cell proliferation.
Dysregulation of JAK1 associates with autoimmune diseases like rheumatoid arthritis and certain cancers. JAK1 inhibitors have been developed as therapeutic agents for these conditions targeting its kinase activity to modulate aberrant signaling. The interaction between JAK1 and other kinases such as JAK2 and transcription factors like STATs highlights its importance in disease mechanisms providing a target for drugs to manage inflammatory and malignant disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNa + IL-4 + pervandadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using ab278781 at 0.001μg/mL.
Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using ab278781 at 0.01µg/mL.
Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using ab278781 at 0.01µg/mL.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com